Standout Papers

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM stud... 2022 2026 2023 2024169
  1. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study (2022)
    Jeremy S. Abramson, Scott R. Solomon et al. Blood

Immediate Impact

5 by Nobel laureates 26 standout
Sub-graph 1 of 12

Citing Papers

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
2 intermediate papers

Works of Sami Ibrahimi being referenced

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
2022
Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study
2018

Author Peers

Author Last Decade Papers Cites
Sami Ibrahimi 258 145 60 32 363
Pim Mutsaers 242 164 36 29 337
Alessandro Crotta 256 109 45 24 346
Pratyush Giri 314 232 83 28 411
Reid W. Merryman 251 223 60 43 403
Max J. Gordon 112 194 160 41 334
Anna Johnston 108 123 60 37 325
Mariana Bastos‐Oreiro 154 110 62 51 326
Moritz Bewarder 113 96 48 42 321
Sandra P. Susanibar-Adaniya 161 126 50 27 301
P. Nelli 209 53 56 29 372

All Works

Loading papers...

Rankless by CCL
2026